CAS: 442876-19-9; 3-Ethyl-4-Iodo-1H-Pyrazole

相似化合物

15802-75-2 2033-45-6 390356-27-1

上下游产品

3-乙基-1H-吡唑 3-Ethyl-1H-Pyrazole 13808-71-4

📜3-乙基-1H-吡唑置于山梨醇酐单棕榈酸酯 Sodium Hydroxide,碘体系中,用 水 作为反应溶剂,化学反应生成 3-乙基-4-碘-1H-吡唑
参考文献:N-(3-(4-Substituted-1-Piperidinyl)-1-Phenylpropyl) Substituted Sulfonamides As Nk-3 Receptor Antagonists
标题:N-(3-(4-Substituted-1-Piperidinyl)-1-Phenylpropyl) Substituted Sulfonamides As Nk-3 Receptor Antagonists
摘要:本发明提供了一种治疗患有疾病(如精神分裂症)的受试者的方法,其中该疾病的治疗需要使用nk-3拮抗剂,包括向该受试者施用化合物i的治疗有效量: 1 其中,通常情况下,Q是 2 R 1 是苄基,苯基,噻吩或咪唑基,可选择地用c 1-4 烷基或卤素(如甲基,氟或溴)取代; R 2 是氢或c 1-4 烷基,如甲基; R 3 是苯基; R 4 是氢; R 5 是氢或c 1-6 烷基羰基,如甲基羰基; X是-so 2-或-c(O)N(R 2)So 2-,其中r 2 最好是氢; Y是键,Ch 2 或z 1,其中z 1 是-n(R F)-,其中r F 是c 1-6 烷基羰基,如乙基羰基;以及 R 6 是苯基,吡唑基,吡啶基,嘧啶基或苯并咪唑基,可选择地用来自c 1-6 烷基和苄基的一个或两个基团取代,如甲基,乙基和苄基; 或其药学上可接受的盐.

专利信息

专利号:US-8445510-B2
优先权日:2010-05-14
标题 :Fused bicyclic kinase inhibitors
发明人：MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING
权利人:MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.